601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)

Clinical trial NCT04667910 · COMPLETED

Trial details

NCT number: NCT04667910
Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Central Retinal Vein Occlusion

Start date: 2021-01-27
Primary completion: 2022-11-16
Enrollment: 60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.